

Khawla S Al-Kuraya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4371462/publications.pdf>

Version: 2024-02-01

77
papers

1,388
citations

394421

19
h-index

377865

34
g-index

77
all docs

77
docs citations

77
times ranked

2350
citing authors

#	ARTICLE	IF	CITATIONS
1	Lymph node ratio is superior to AJCC N stage for predicting recurrence in papillary thyroid carcinoma. <i>Endocrine Connections</i> , 2022, 11, .	1.9	7
2	Genetic risk of cancer: a tale of diversity from the Middle East. <i>Lancet Oncology</i> , The, 2022, , .	10.7	0
3	TERT Promoter Mutations Are an Independent Predictor of Distant Metastasis in Middle Eastern Papillary Thyroid Microcarcinoma. <i>Frontiers in Endocrinology</i> , 2022, 13, 808298.	3.5	11
4	APOBEC SBS13 Mutational Signatureâ€™A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma. <i>Cancers</i> , 2022, 14, 1584.	3.7	4
5	Male Sex Is an Independent Predictor of Recurrence-Free Survival in Middle Eastern Papillary Thyroid Carcinoma. <i>Frontiers in Endocrinology</i> , 2022, 13, 777345.	3.5	5
6	CHD4 Predicts Aggressiveness in PTC Patients and Promotes Cancer Stemness and EMT in PTC Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 504.	4.1	5
7	Prognostic Value and Function of KLF5 in Papillary Thyroid Cancer. <i>Cancers</i> , 2021, 13, 185.	3.7	5
8	PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers. <i>Journal of Personalized Medicine</i> , 2021, 11, 73.	2.5	7
9	PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer. <i>Cells</i> , 2021, 10, 229.	4.1	8
10	Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation. <i>Scientific Reports</i> , 2021, 11, 3750.	3.3	22
11	PD-L1 Expression Is an Independent Marker for Lymph Node Metastasis in Middle Eastern Endometrial Cancer. <i>Diagnostics</i> , 2021, 11, 394.	2.6	2
12	PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by BRAFV600E Mutation. <i>Cancers</i> , 2021, 13, 555.	3.7	18
13	NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC. <i>European Journal of Endocrinology</i> , 2021, 184, 503-511.	3.7	10
14	High Expression of Cyclin D1 is an Independent Marker for Favorable Prognosis in Middle Eastern Breast Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3309-3318.	2.0	7
15	Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2021, 14, 69.	3.0	5
16	Recurrent Somatic MAP2K1 Mutations in Papillary Thyroid Cancer and Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 670423.	2.8	10
17	Abstract 1176: CHD4 predicts aggressiveness in PTC patients and promotes cancer stemness and EMT in PTC cells. , 2021, , .		0
18	Abstract 730: Annual hazard rate of recurrence in Middle-Eastern papillary thyroid cancer over a long-term follow-up. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
19	Abstract 3190: PD-L1 protein expression in Middle Eastern breast cancer predicts favorable outcome in triple negative breast cancer. , 2021, , .		0
20	Abstract 3186: Differential expression of PD-L1 between primary and metastatic Middle-Eastern epithelial ovarian carcinoma and its clinico-pathological correlation. , 2021, , .		0
21	Abstract 1963: High expression of Cyclin D1 is an independent marker for favorable prognosis in Middle Eastern breast cancer. , 2021, , .		0
22	Loss of ZNF677 Expression Is an Independent Predictor for Distant Metastasis in Middle Eastern Papillary Thyroid Carcinoma Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7833.	4.1	6
23	Abstract 2425: Prevalence of NTRK fusions and clinico-pathological characteristics of Middle Eastern papillary thyroid cancer revealed enrichment in BRAF wild-type PTC. , 2021, , .		0
24	Loss of ZNF677 expression is a predictive biomarker for lymph node metastasis in Middle Eastern Colorectal Cancer. <i>Scientific Reports</i> , 2021, 11, 22346.	3.3	4
25	Microscopic Extrathyroidal Extension Results in Increased Rate of Tumor Recurrence and Is an Independent Predictor of Patient's Outcome in Middle Eastern Papillary Thyroid Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 724432.	2.8	9
26	Risk Factors for Central Lymph Node Metastases and Benefit of Prophylactic Central Lymph Node Dissection in Middle Eastern Patients With cNO Papillary Thyroid Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 819824.	2.8	6
27	Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population. <i>Genomics</i> , 2020, 112, 1746-1753.	2.9	10
28	Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid Cancer. <i>Thyroid</i> , 2020, 30, 42-56.	4.5	31
29	APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109572.	5.6	15
30	Clonal Evolution and Timing of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 2938.	3.7	9
31	Prognostic Significance of COX-2 Overexpression in BRAF-Mutated Middle Eastern Papillary Thyroid Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9498.	4.1	4
32	Krupple-Like Factor 5 is a Potential Therapeutic Target and Prognostic Marker in Epithelial Ovarian Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 598880.	3.5	7
33	Annual Hazard Rate of Recurrence in Middle Eastern Papillary Thyroid Cancer over a Long-Term Follow-Up. <i>Cancers</i> , 2020, 12, 3624.	3.7	13
34	The study of Lynch syndrome in a special population reveals a strong founder effect and an unusual mutational mechanism in familial adenomatous polyposis. <i>Gut</i> , 2020, 69, 2048-2049.	12.1	3
35	POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1368.	1.2	9
36	Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases. <i>British Journal of Cancer</i> , 2020, 122, 1219-1230.	6.4	56

#	ARTICLE	IF	CITATIONS
37	POLE and POLD1 pathogenic variants in the proofreading domain in papillary thyroid cancer. <i>Endocrine Connections</i> , 2020, 9, 923-932.	1.9	7
38	SUN-132 KLF5 Is a Poor Prognostic Marker and Therapeutic Target for Middle Eastern Papillary Thyroid Carcinoma. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
39	Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma. <i>European Journal of Cancer</i> , 2019, 117, 133-144.	2.8	17
40	Evolution and Impact of Subclonal Mutations in Papillary Thyroid Cancer. <i>American Journal of Human Genetics</i> , 2019, 105, 959-973.	6.2	22
41	Zamzam water protects cancer cells from chemotherapy-induced apoptosis via mitogen-activated protein kinase-dependent pathway. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109376.	5.6	2
42	TGF β -induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1312-1322.	4.1	20
43	Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East. <i>Human Mutation</i> , 2019, 40, 729-733.	2.5	11
44	Germline POLE and POLD1 proofreading domain mutations in endometrial carcinoma from Middle Eastern region. <i>Cancer Cell International</i> , 2019, 19, 334.	4.1	12
45	<i>MED12</i> is recurrently mutated in Middle Eastern colorectal cancer. <i>Gut</i> , 2018, 67, gutjnl-2016-313334.	12.1	12
46	Downregulation of SKP2 in Papillary Thyroid Cancer Acts Synergistically With TRAIL on Inducing Apoptosis via ROS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1530-1544.	3.6	10
47	Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer. <i>International Journal of Cancer</i> , 2018, 142, 2028-2039.	5.1	50
48	FoxM1 and β -catenin predicts aggressiveness in Middle Eastern ovarian cancer and their co-targeting impairs the growth of ovarian cancer cells. <i>Oncotarget</i> , 2018, 9, 3590-3604.	1.8	18
49	FoxM1 is an independent poor prognostic marker and therapeutic target for advanced Middle Eastern breast cancer. <i>Oncotarget</i> , 2018, 9, 17466-17482.	1.8	15
50	Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment. <i>Oncotarget</i> , 2018, 9, 37319-37332.	1.8	17
51	Response to Yehia et al.. <i>American Journal of Human Genetics</i> , 2017, 100, 564-565.	6.2	0
52	Expanding the spectrum of germline variants in cancer. <i>Human Genetics</i> , 2017, 136, 1431-1444.	3.8	23
53	XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis. <i>BMC Cancer</i> , 2017, 17, 640.	2.6	39
54	Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis. <i>American Journal of Human Genetics</i> , 2016, 98, 1170-1180.	6.2	41

#	ARTICLE	IF	CITATIONS
55	Identification of novel <i>BRCA</i> founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis. <i>International Journal of Cancer</i> , 2016, 139, 1091-1097.	5.1	52
56	Reply to specific gene patterns and molecular pathways related to human carcinogenesis in different populations among various geographic locations. <i>Cancer</i> , 2016, 122, 1135-1137.	4.1	0
57	ALK alteration is a frequent event in aggressive breast cancers. <i>Breast Cancer Research</i> , 2015, 17, 127.	5.0	29
58	Molecular markers and pathway analysis of colorectal carcinoma in the Middle East. <i>Cancer</i> , 2015, 121, 3799-3808.	4.1	19
59	Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer. <i>Molecular Medicine</i> , 2015, 21, 466-478.	4.4	10
60	Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 541-553.	2.5	43
61	Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer. <i>Cancer</i> , 2015, 121, 1762-1771.	4.1	34
62	Role of X-Linked Inhibitor of Apoptosis as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E974-E985.	3.6	34
63	Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells. <i>Molecular Cancer</i> , 2015, 14, 131.	19.2	33
64	High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma. <i>Carcinogenesis</i> , 2014, 35, 1564-1572.	2.8	40
65	A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. <i>Molecular Cancer</i> , 2014, 13, 168.	19.2	31
66	FoxM1 and Its Association with Matrix Metalloproteinases (MMP) Signaling Pathway in Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1-E13.	3.6	56
67	Cross-Talk between NFκB and the PI3-Kinase/AKT Pathway Can Be Targeted in Primary Effusion Lymphoma (PEL) Cell Lines for Efficient Apoptosis. <i>PLoS ONE</i> , 2012, 7, e39945.	2.5	138
68	Clinicopathological Analysis of Papillary Thyroid Cancer with <i>PIK3CA</i> Alterations in a Middle Eastern Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 611-618.	3.6	169
69	Fatty Acid Synthase and AKT Pathway Signaling in a Subset of Papillary Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4088-4097.	3.6	65
70	Proteasome Inhibitor Treatment Down-Regulates S-Phase Kinase-Associated Protein 2 Causing Inhibition of Proliferation and Induces Apoptosis in Primary Effusion Lymphoma. <i>Blood</i> , 2006, 108, 4616-4616.	1.4	0
71	Significance of Ubiquitin Ligase Subunit SKP-2 Proto-Oncogene and Proliferative Marker Ki67 Expression in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2006, 108, 4343-4343.	1.4	0
72	Colorectal carcinoma from Saudi Arabia. Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2006, 27, 323-8.	1.1	10

#	ARTICLE	IF	CITATIONS
73	Apigenin Induces Apoptosis in Primary Effusion Lymphoma.. Blood, 2005, 106, 4807-4807.	1.4	0
74	Role of Phosphatidylinositol 3- Kinase/AKT Pathway in Diffuse Large B-Cell Lymphoma Survival.. Blood, 2005, 106, 4808-4808.	1.4	1
75	Wingless signaling pathway family relation to colon cancer. Have we come full circle?. Journal of King Abdulaziz University, Islamic Economics, 2005, 26, 19-23.	1.1	0
76	Prognostic Molecular Features in Diffuse Large B-Cell Lymphoma from Saudi Arabia.. Blood, 2004, 104, 4609-4609.	1.4	0
77	Epstein-Barr Virus Infection Is Not the Sole Cause of High Prevalence for Hodgkinâ€™s Lymphoma in Saudi Arabia.. Blood, 2004, 104, 3120-3120.	1.4	0